Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Revenue (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Revenue for 12 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 15.29% year-over-year to $1.3 million, compared with a TTM value of $5.2 million through Sep 2025, up 12.26%, and an annual FY2024 reading of $5.0 million, up 13.27% over the prior year.
  • Revenue was $1.3 million for Q3 2025 at Arcadia Biosciences, down from $1.5 million in the prior quarter.
  • Across five years, Revenue topped out at $4.3 million in Q4 2021 and bottomed at -$5.8 million in Q4 2022.
  • Average Revenue over 5 years is $1.2 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Revenue soared 656.69% in 2021, then tumbled 235.16% in 2022.
  • Year by year, Revenue stood at $4.3 million in 2021, then crashed by 235.16% to -$5.8 million in 2022, then soared by 113.37% to $777000.0 in 2023, then skyrocketed by 56.37% to $1.2 million in 2024, then increased by 7.16% to $1.3 million in 2025.
  • Business Quant data shows Revenue for RKDA at $1.3 million in Q3 2025, $1.5 million in Q2 2025, and $1.2 million in Q1 2025.